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Background: TRAIL (TNFSF10) and osteoprotegerin (OPG, TNFRSF11B) and are pro- and anti- apoptotic proteins implicated in myocardial 
pathobiology including heart valve disease. Our gene expression studies in patients (pts) undergoing aortic valve replacement for aortic regurgitation 
(AR) or stenosis (AS) suggest a reciprocal expression of these genes. We hypothesized that gene expression reflected in plasma protein levels would 
correlate with changes in cardiac geometry and symptoms associated with clinically significant AR and AS and thus provide a biochemical means of 
identifying left ventricular (LV) decompensation.
Method: Plasma was obtained prior to cardioplegia and LV free wall biopsy from pts with normal LV systolic function undergoing AVR for AR (n=9) 
or AS (n=9). Pts undergoing bypass grafting for clinically stable CAD without prior myocardial infarction (n=6) served as controls. LV geometry 
(LVEDDI) and symptoms (rest/stress dyspnea, orthopnea, PND) were determined for all patients. Plasma TRAIL and OPG levels were measured using 
ELISA. Subgroup differences were evaluated using the Mann-Whitney test; other associations were tested by Spearman rank order correlation. P 
values ≤ 0.05 were considered statistically significant.
Results: TRAIL was 29% higher in AR compared with AS and 8% lower compared with CAD, but these differences did not reach statistical 
significance (NS). However, OPG was lower in AR than in AS (23%, p=0.031) and CAD (32%, p=0.010). TRAIL/OPG ratio in AR was >2X the ratio in AS 
(p=0.024). Among all pts, TRAIL and TRAIL/OPG ratio correlated with LVEDDI (l = 0.476, p = .034 andl = 0.526 p = .017, respectively). TRAIL and 
TRAIL/OPG ratio in symptomatic AR were 4 times greater than levels in asymptomatic AR (both p=0.014).
Conclusion: Our findings suggest that increases in the plasma concentration of TRAIL and TRAIL/OPG ratio are associated with myocardial dilation 
and symptom status in AR. Further studies are necessary to determine whether TRAIL, OPG and their ratios are more sensitive predictors of clinical 
deterioration than myocardial geometry and symptom development and, therefore, useful as guides for surgical intervention.
